Papillomavirus vaccines

The Papillomaviruses

Volumn , Issue , 2007, Pages 337-369

  Schiller, John ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83055160968     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-36523-7_14     Document Type: Chapter

References (131)

1. ACOG Practice Bulletin. (April 2005). Clinical management guidelines for obstetriciangynecologists. Number 61. Human papillomavirus. Obstet. Gynecol. 105(4), 905-918.
2. Androphy, E. J., Hubbert, N. L., Schiller, J. T., and Lowy, D. R. (1987). Identification of the HPV16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J. 6:989-992.
3. Arbeit, J. M., Howley, P. M., and Hanahan, D. (1996). Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc. Natl. Acad. Sci. U S A 93(7):2930-2935.
4. Azoury-Ziadeh, R., Herd, K., Fernando, G. J., Lambert, P., Frazer, I. H., and Tindle, R. W. (2001). Low level expression of human papillomavirus type16 (HPV16) E6 insquamous epithelium does not elicit E6 specific B- or T-helper immunological responses, or influence the outcome of immunisation with E6 protein. Virus Res. 73(2):189-199.
5. Baldwin, P. J., Van Der Burg, S. H., Boswell, C. M., Offringa, R., Hickling, J. K., Dobson, J., Roberts, J. S., Latimer, J. A., Moseley, R. P., Coleman, N., Stanley, M. A., and Sterling, J. C. (2003). Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res. 9(14):5205-5213.
6. Barton, G. M., and Medzhitov, R. (2002). Toll-like receptors and their ligands. Curr. Top. Microbiol. Immunol. 270:81-92.
7. Baseman, J. G., and Koutsky, L. A. (2005). The epidemiology of human papillomavirus infections. J. Clin. Virol. 32(Suppl 1):S16-S24.
8. Baud, D., Ponci, F., Bobst, M., De Grandi, P., and Nardelli-Haefliger, D. (2004). Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J. Virol. 78(23):12901-1209.
9. Belyakov, I. M., and Berzofsky, J. A. (2004). Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20(3):247-253.
10. Bontkes, H. J., Walboomers, J. M., Meijer, C. J., Helmerhorst, T. J., and Stern, P. L. (1998). Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 351(9097):187-188.
11. Borysiewicz, L. K., Fiander, A., Nimako, M., Man, S., Wilkinson, G. W., Westmoreland, D., Evans, A. S., Adams, M., Stacey, S. N., Boursnell, M. E., Rutherford, E., Hickling, J. K., and Inglis, S. C. (1996). A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347(9014):1523-1527.
12. Bosch, F. X., and De Sanjose, S. (2003). Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J. Natl. Cancer Inst. Monogr. 31:3-13.
13. Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J., and Shah, K. V. (2002). The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55(4):244-265.
14. Brandau, D. T., Jones, L. S., Wiethoff, C. M., Rexroad, J., and Middaugh, C. R. (2003). Thermal stability of vaccines. J. Pharm. Sci. 92(2):218-231.
15. Brandsma, J. L. (1994). Animal models of Human-Papillomavirus-associated oncogenesis. Intervirology 37:189-200.
16. Brandsma, J. L., Shlyankevich, M., Zhang, L., Slade, M. D., Goodwin, E. C., Peh, W., and Deisseroth, A. B. (2004). Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J. Virol. 78(1):116-123.
17. Breitburd, F., Kirnbauer, R., Hubbert, N. L., Nonnenmacher, B., Trin-Dinh-Desmarquet, C., Orth, G., Schiller, J. T., and Lowy, D. R. (1995). Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69(6):3959-3963.
18. Christensen, N. D., Kirnbauer, R., Schiller, J. T., Ghim, S. J., Schlegel, R., Jenson, A. B., and Kreider, J. W. (1994). Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205:329-335.
19. Chu, N. R., Wu, H. B., Wu, T., Boux, L. J., Siegel, M. I., and Mizzen, L. A. (2000). Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 121(2):216-225.
20. Corona Gutierrez, C. M., Tinoco, A., Navarro, T., Contreras, M. L., Cortes, R. R., Calzado, P., Reyes, L., Posternak, R., Morosoli, G., Verde, M. L., and Rosales, R. (2004). Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum. Gene Ther. 15(5):421-431.
21. Cox, J. T. (2002a). Management of precursor lesions of cervical carcinoma: history, host defense, and a survey of modalities. Obstet. Gynecol. Clin. North Am. 29(4):751-785.
22. Cox, J. T. (2002b). Management of women with cervical cancer precursor lesions. Obstet. Gynecol. Clin. North Am. 29(4):787-816.
23. Da Silva, D. M., Pastrana, D. V., Schiller, J. T., and Kast, W. M. (2001). Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 290(2):350-360.
24. Davidson, E. J., Boswell, C. M., Sehr, P., Pawlita, M., Tomlinson, A. E., McVey, R. J., Dobson, J., Roberts, J. S., Hickling, J., Kitchener, H. C., and Stern, P. L. (2003). Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. 63(18):6032-6041.
25. Davis, K., Dickman, E. D., Ferris, D., and Dias, J. K. (2004). Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J. Low Genit. Tract Dis. 8(3):188-194.
26. De Bruijn, M. L. H., Greenstone, H. L., Vermeulen, H., Melief, C. J. M., Lowy, D. R., Schiller, J. T., and Kast, W. M. (1998). L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250:371-376.
27. De Jong, A., O'Neill, T., Khan, A. Y., Kwappenberg, K. M., Chisholm, S. E., Whittle, N. R., Dobson, J. A., Jack, L. C., St Clair Roberts, J. A., Offringa, R., Van Der Burg, S. H., and Hickling, J. K. (2002). Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20(29-30):3456-3464.
28. De Jong, A., Van Poelgeest, M. I., Van Der Hulst, J. M., Drijfhout, J. W., Fleuren, G. J., Melief, C. J., Kenter, G., Offringa, R., and Van Der Burg, S. H. (2004). Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 64(15):5449-5455.
29. Doorbar, J. (2005). The papillomavirus life cycle. J. Clin. Virol. 32(Suppl 1):S7-S15.
30. Dunn, L. A., Evander, M., Tindle, R. W., Bulloch, A. L., De Kluyver, R. L., Fernando, G. J., Lambert, P. F., and Frazer, I. H. (1997). Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology 235(1):94-103.
31. Ehreth, J. (2003). The value of vaccination: a global perspective. Vaccine 21(27-28):4105-4117.
32. Eiben, G. L., Velders, M. P., Schreiber, H., Cassetti, M. C., Pullen, J. K., Smith, L. R., and Kast, W. M. (2002). Establishment of an HLA-A∗0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A∗0201 transgenic mice. Cancer Res. 62(20):5792-5799.
33. Evans, T. G., Bonnez, W., Rose, R. C., Koenig, S., Demeter, L., Suzich, J. A., O'Brien, D., Campbell, M., White, W. I., Balsley, J., and Reichman, R. C. (2001). A Phase 1 Study of a Recombinant Viruslike Particle Vaccine against Human Papillomavirus Type 11 in Healthy Adult Volunteers. J. Infect. Dis. 183(10):1485-1493.
34. Frazer, I. H., Kluyver, R. D., Leggatt, G. R., Yang Guo, H., Dunn, L., White, O., Harris, C., Liem, A., and Lambert, P. (2001). Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. J. Immunol. 167(11):6180-6187.
35. Frazer, I. H., Quinn, M., Nicklin, J. L., Tan, J., Perrin, L. C., Ng, P., O'Connor, V. M., White, O., Wendt, N., Martin, J., Crowley, J. M., Edwards, S. J., McKenzie, A. W., Mitchell, S. V., Maher, D. W., Pearse, M. J., and Basser, R. L. (2004). Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23(2):172-181.
36. Garcia, F., Petry, K. U., Muderspach, L., Gold, M. A., Braly, P., Crum, C. P., Magill, M., Silverman, M., Urban, R. G., Hedley, M. L., and Beach, K. J. (2004). ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: A randomized controlled trial. Obstet. Gynecol. 103(2):317-326.
37. Garnett, G. P. (2005). Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J. Infect. Dis. 191(Suppl 1):S97-106.
38. Gillison, M. L., and Shah, K. V. (2003). Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J. Natl. Cancer Inst. Monogr. 31:57-65.
39. Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., and Franco, E. (2004). Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl. Cancer Inst. 96(8):604-615.
40. Greenstone, H. L., Nieland, J. D., De Visser, K. E., De Bruijn, M. L. H., Kirnbauer, R., Roden, R. B. S., Lowy, D. R., Kast, W. M., and Schiller, J. T. (1998). Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. U S A 95(4):1800-1805.
41. Hagensee, M. E., Yaegashi, N., and Galloway, D. A. (1993). Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67(1):315-322.
42. Hallez, S., Simon, P., Maudoux, F., Doyen, J., Noel, J. C., Beliard, A., Capelle, X., Buxant, F., Fayt, I., Lagrost, A. C., Hubert, P., Gerday, C., Burny, A., Boniver, J., Foidart, J. M., Delvenne, P., and Jacobs, N. (2004). Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol. Immunother. 53(7):642-650.
43. Han, R., Cladel, N. M., Reed, C. A., Peng, X., Budgeon, L. R., Pickel, M., and Christensen, N. D. (2000a). DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J. Virol. 74(20):9712-9716.
44. Han, R., Reed, C. A., Cladel, N. M., and Christensen, N. D. (2000b). Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: Protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. Vaccine 18(26):2937-2944.
45. Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., Roteli-Martins, C. M., Teixeira, J., Blatter, M. M., Korn, A. P., Quint, W., and Dubin, G. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364(9447):1757-1765.
46. Harro, C. D., Pang, Y. Y., Roden, R. B., Hildesheim, A., Wang, Z., Reynolds, M. J., Mast, T. C., Robinson, R., Murphy, B. R., Karron, R. A., Dillner, J., Schiller, J. T., and Lowy, D. R. (2001). Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93(4):284-292.
47. Hofmann, K., Cook, J., Joyce, J., Brown, D., Schultz, L., George, H., Rosolowsky, M., Fife, K., and Jansen, K. (1995). Sequence determination of Human Papillomavirus 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 209:506-518.
48. Hunt, S. (2001). Technology evaluation: HspE7, StressGen Biotechnologies Corp. Curr. Opin. Mol. Ther. 3(4):413-417.
49. Kahn, J. A., Rosenthal, S. L., Hamann, T., and Bernstein, D. I. (2003). Attitudes about human papillomavirus vaccine in young women. Int. J. STD AIDS 14(5):300-306.
50. Kao, J. H., and Chen, D. S. (2002). Global control of hepatitis B virus infection. Lancet Infect. Dis. 2(7):395-403.
51. Kast, W. M., Brandt, R. M., Drijfhout, J. W., and Melief, C. J. (1993). Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J. Immunother. 14:115-120.
52. Kaufmann, A. M., Stern, P. L., Rankin, E. M., Sommer, H., Nuessler, V., Schneider, A., Adams, M., Onon, T. S., Bauknecht, T., Wagner, U., Kroon, K., Hickling, J., Boswell, C. M., Stacey, S. N., Kitchener, H. C., Gillard, J., Wanders, J., Roberts, J. S., and Zwierzina, H. (2002). Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res. 8(12):3676-3685.
53. Kawana, K., Kawana, Y., Yoshikawa, H., Taketani, Y., Yoshiike, K., and Kanda, T. (2001). Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine 19(11-12):1496-1502.
54. Kawana, K., Yasugi, T., Kanda, T., Kino, N., Oda, K., Okada, S., Kawana, Y., Nei, T., Takada, T., Toyoshima, S., Tsuchiya, A., Kondo, K., Yoshikawa, H., Tsutsumi, O., and Taketani, Y. (2003). Safety and immunogenicity of a peptide containing the crossneutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 21(27-28):4256-4260.
55. Khan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M., Scott, D. R., Rush, B. B., Glass, A. G., and Schiffman, M. (2005). The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97(14):1072-1079.
56. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., and Schiller, J. T. (1992). Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U S A 89(24):12180-12184.
57. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R. B. S., Durst, M., Gissmann, L., Lowy, D. R., and Schiller, J. T. (1993). Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67(12):6929-6936.
58. Kirnbauer, R., Chandrachud, L., O'Neil, B., Wagner, E., Grindlay, G., Armstrong, A., McGarvie, G., Schiller, J., Lowy, D., and Campo, M. (1996). Virus-likeparticles of Bovine Papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219:37-44.
59. Klencke, B. J., and Palefsky, J. M. (2003). Anal cancer: An HIV-associated cancer. Hematol. Oncol. Clin. North Am. 17(3):859-872.
60. Klencke, B., Matijevic, M., Urban, R. G., Lathey, J. L., Hedley, M. L., Berry, M., Thatcher, J., Weinberg, V., Wilson, J., Darragh, T., Jay, N., Da Costa, M., and Palefsky, J. M. (2002). Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res. 8(5):1028-1037.
61. Koopman, L. A., Corver, W. E., Van Der Slik, A. R., Giphart, M. J., and Fleuren, G. J. (2000). Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med. 191(6):961-976.
62. Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., and Jansen, K. U. (2002). A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347(21):1645-1651.
63. Kulasingam, S. L., and Myers, E. R. (2003). Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290(6):781-789.
64. Lenz, P., Day, P. M., Pang, Y. S., Frye, S. A., Jensen, P. N., Lowy, D. R., and Schiller, J. T. (2001). Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166:5346-5355.
65. Lin, K.-Y., Guarnieri, F. G., Staveley-O'Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., and Wu, T.-C. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21-26.
66. Liu, M. A. (2003). DNA vaccines: A review. J. Intern. Med. 253(4):402-410.
67. Liu, X. S., Xu, Y., Hardy, L., Khammanivong, V., Zhao, W., Fernando, G. J., Leggatt, G. R., and Frazer, I. H. (2003). IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J. Immunol. 171(9):4765-4772.
68. Liu, M., Acres, B., Balloul, J. M., Bizouarne, N., Paul, S., Slos, P., and Squiban, P. (2004). Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. U S A 101(Suppl 2):14567-14571.
69. Liu, D. W., Chang, J. L., Tsao, Y. P., Huang, C. W., Kuo, S. W., and Chen, S. L. (2005). Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody. Int. J. Cancer 113(1):93-100.
70. Longworth, M. S., and Laimins, L. A. (2004). Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 68(2):362-372.
71. Maciag, P. C., and Paterson, Y. (2005). Technology evaluation: HspE7 (Stressgen). Curr. Opin. Mol. Ther. 7(3):256-263.
72. Matsumoto, K., Leggatt, G. R., Zhong, J., Liu, X., De Kluyver, R. L., Peters, T., Fernando, G. J., Liem, A., Lambert, P. F., and Frazer, I. H. (2004). Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. J. Natl. Cancer Inst. 96(21):1611-1619.
73. Mestecky, J., and Russell, M. W. (2000). Induction of mucosal immune responses in the human genital tract. FEMS Imm. Med. Micro. 27:351-355.
74. Mocellin, S., Mandruzzato, S., Bronte, V., Lise, M., and Nitti, D. (2004). Part I: Vaccines for solid tumours. Lancet Oncol. 5(11):681-689.
75. Moingeon, P., Almond, J., and De Wilde, M. (2003). Therapeutic vaccines against infectious diseases. Curr. Opin. Microbiol. 6(5):462-471.
76. Moore, R. A., Walcott, S., White, K. L., Anderson, D. M., Jain, S., Lloyd, A., Topley, P., Thomsen, L., Gough, G. W., and Stanley, M. A. (2003). Therapeutic immunisation with COPV early genes by epithelial DNA delivery. Virology 314(2):630-635.
77. Muderspach, L., Wilczynski, S., Roman, L., Bade, L., Felix, J., Small, L. A., Kast, W. M., Fascio, G., Marty, V., and Weber, J. (2000). A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6(9):3406-3416.
78. Muller, M., Zhou, J., Reed, T. D., Rittmuller, C., Burger, A., Gabelsberger, J., Braspenning, J., and Gissmann, L. (1997). Chimeric papillomavirus-like particles. Virology 234:93-111.
79. Munoz, N., Bosch, F. X., Castellsague, X., Diaz, M., De Sanjose, S., Hammouda, D., Shah, K. V., and Meijer, C. J. (2004). Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111(2):278-285.
80. Nakagawa, M., Stites, D. P., Patel, S., Farhat, S., Scott, M., Hills, N. K., Palefsky, J. M., and Moscicki, A. B. (2000). Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J. Infect. Dis. 182(2):595-598.
81. Nardelli-Haefliger, D., Lurati, F., Wirthner, D., Spertini, F., Schiller, J. T., Lowy, D. R., Ponci, F., and De Grandi, P. (2005). Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23(28):3634-3641.
82. Nardelli-Haefliger, D., Roden, R. B. S., Benyacoub, J., Sahli, R., Kraehenhuhl, J. P., Schiller, J. T., Lachat, P., Potts, A., and De Grande, P. (1997). Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Inf. Immun. 65:3328-3336.
83. Nardelli-Haefliger, D., Wirthner, D., Schiller, J. T., Lowy, D. R., Hildesheim, A., Ponci, F., and De Grandi, P. (2003). Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. 95(15):1128-1137.
84. Nicholls, P. K., Moore, P. F., Anderson, D. M., Moore, R. A., Parry, N. R., Gough, G. W., and Stanley, M. A. (2001). Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 283(1):31-39.
85. Osen, W., Peiler, T., Ohlschlager, P., Caldeira, S., Faath, S., Michel, N., Muller, M., Tommasino, M., Jochmus, I., and Gissmann, L. (2001). A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 19(30):4276-4286.
86. Pagliusi, S. R., and Teresa Aguado, M. (2004). Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23(5):569-578.
87. Palefsky, J. M., and Holly, E. A. (2003). Chapter 6: Immunosuppression and co-infection with HIV. J. Natl. Cancer Inst. Monogr. 31:41-46.
88. Palker, T. J., Monteiro, J. M., Martin, M. M., Kakareka, C., Smith, J. F., Cook, J. C., Joyce, J. G., and Jansen, K. U. (2001). Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. Vaccine 19(27):3733-3743.
89. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2001). Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94(2):153-156.
90. Pastrana, D. V., Buck, C. B., Pang, Y. Y., Thompson, C. D., Castle, P. E., Fitz Gerald, P. C., Kruger Kjaer, S., Lowy, D. R., and Schiller, J. T. (2004). Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321(2):205-216.
91. Pastrana, D. V., Gambhira, R., Buck, C. B., Pang, Y. Y., Thompson, C. D., Culp, T. D., Christensen, N. D., Lowy, D. R., Schiller, J. T., and Roden, R. B. (2005). Crossneutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337(2):365-372.
92. Peh, W. L., Middleton, K., Christensen, N., Nicholls, P., Egawa, K., Sotlar, K., Brandsma, J., Percival, A., Lewis, J., Liu, W. J., and Doorbar, J. (2002). Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J. Virol. 76(20):10401-10416.
93. Pilacinski, W. P., Glassman, D. L., Glassman, K. F., Reed, D. E., Lum, M. A., Marshall, R. F., Muscoplat, C. C., and Faras, A. J. (1986). Immunization against bovine papillomavirus infection. In Papillomaviruses: Ciba Foundation Symposium 120. Chichester: Wiley, pp. 136-156.
94. Pinto, L. A., Edwards, J., Castle, P. E., Harro, C. D., Lowy, D. R., Schiller, J. T., Wallace, D., Kopp, W., Adelsberger, J. W., Baseler, M. W., Berzofsky, J. A., and Hildesheim, A. (2003). Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 188(2):327-338.
95. Revaz, V., and Nardelli-Haefliger, D. (2005). The importance of mucosal immunity in defense against epithelial cancers. Curr. Opin. Immunol. 17(2):175-179.
96. Rivera, A., and Tyring, S. K. (2004). Therapy of cutaneous human Papillomavirus infections. Dermatol. Ther. 17(6):441-448.
97. Roden, R. B. S., Greenstone, H. L., Kirnbauer, R., Booy, F. P., Jessie, J., Lowy, D. R., and Schiller, J. T. (1996). In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70:5875-5883.
98. Roden, R. B., Lowy, D. R., and Schiller, J. T. (1997). Papillomavirus is resistant to desiccation. J. Infect. Dis. 176(4):1076-1079.
99. Roden, R. B., Yutzy, W. I., Fallon, R., Inglis, S., Lowy, D. R., and Schiller, J. T. (2000). Minor capsid protein of human genital papillomaviruses contains subdominant, crossneutralizing epitopes. Virology 270(2):254-257.
100. Roden, R. B., Ling, M., and Wu, T. C. (2004). Vaccination to prevent and treat cervical cancer. Hum. Pathol. 35(8):971-982.
101. Rose, R. C., Bonnez, W., Reichman, R. C., and Garcea, R. L. (1993). Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of virus-like particles. J. Virol. 67(4):1936-1944.
102. Rose, R. C., Reichman, R. C., and Bonnez, W. (1994). Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J. Gen. Virol. 75(Pt 8):2075-2079.
103. Rubben, A., Kalka, K., Spelten, B., and Grussendorf-Conen, E. I. (1997). Clinical features and age distribution of patients with HPV 2/27/57-induced common warts. Arch. Dermatol. Res. 289(6):337-340.
104. Salit, R. B., Kast, W. M., and Velders, M. P. (2002). Ins and outs of clinical trials with peptide-based vaccines. Front. Biosci. 7:e204-e213.
105. Schiffman, M., and Kjaer, S. K. (2003). Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J. Natl. Cancer Inst. Monogr. 31:14-19.
106. Schiffman, M., Khan, M. J., Solomon, D., Herrero, R., Wacholder, S., Hildesheim, A., Rodriguez, A. C., Bratti, M. C., Wheeler, C. M., and Burk, R. D. (2005). A study of the impact of adding HPV types to cervical cancer screening and triage tests. J. Natl. Cancer Inst. 97(2):147-150.
107. Schiller, J. T., and Davies, P. (2004). Delivering on the promise: HPV vaccines and cervical cancer. Nat. Rev. Microbiol. 2(4):343-347.
108. Silverman, D. A., and Pitman, M. J. (2004). Current diagnostic and management trends for recurrent respiratory papillomatosis. Curr. Opin. Otolaryngol. Head Neck Surg. 12(6):532-537.
109. Smyth, L. J., Van Poelgeest, M. I., Davidson, E. J., Kwappenberg, K. M., Burt, D., Sehr, P., Pawlita, M., Man, S., Hickling, J. K., Fiander, A. N., Tristram, A., Kitchener, H. C., Offringa, R., Stern, P. L., and Van Der Burg, S. H. (2004). Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin. Cancer Res. 10(9):2954-2961.
110. Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, F. Y., Slaoui, M., Denis, M., Vandepapeliere, P., Dubin, G., and Glaxo-Smith-Kline Herpes Vaccine Efficacy Study Group. (2002). Glycoprotein-D-adjuvant vaccine to prevent genital herpes [comment]. N. Engl. J. Med. Online 347(21):1652-1661.
111. Stanley, M. A. (2001). Immunobiology of papillomavirus infections. J. Reprod. Immunol. 52(1-2):45-59.
112. Steller, M. A., Gurski, K. J., Murakami, M., Daniel, R. W., Shah, K. V., Celis, E., Sette, A., Trimble, E. L., Park, R. C., and Marincola, F. M. (1998). Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin. Cancer Res. 4(9):2103-2109.
113. Stern, P. L., Brown, M., Stacey, S. N., Kitchener, H. C., Hampson, I., Abdel-Hady, E. S., and Moore, J. V. (2000). Natural HPV immunity and vaccination strategies. J. Clin. Virol. 19(1-2):57-66.
114. Sturesson, C., Artursson, P., Ghaderi, R., Johansen, K., Mirazimi, A., Uhnoo, I., Svensson, L., Albertsson, A. C., and Carlfors, J. (1999). Encapsulation of rotavirus into poly (lactide-co-glycolide) microspheres. J. Control Release 59(3):377-389.
115. Suzich, J. A., Ghim, S., Palmer-Hill, F. J., White, W. I., Tamura, J. K., Bell, J., Newsome, J. A., Jenson, A. B., and Schlegel, R. (1995). Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U S A 92:11553-11557.
116. Syrjanen, S. (2005). Human papillomavirus (HPV) in head and neck cancer. J. Clin. Virol. 32(Suppl 1):S59-S66.
117. Tobery, T. W., Smith, J. F., Kuklin, N., Skulsky, D., Ackerson, C., Huang, L., Chen, L., Cook, J. C., McClements, W. L., and Jansen, K. U. (2003). Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. Vaccine 21(13-14):1539-1547.
118. Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., Skjeldestad, F. E., Olsson, S. E., Steinwall, M., Brown, D. R., Kurman, R. J., Ronnett, B. M., Stoler, M. H., Ferenczy, A., Harper, D. M., Tamms, G. M., Yu, J., Lupinacci, L., Railkar, R., Taddeo, F. J., Jansen, K. U., Esser, M. T., Sings, H. L., Saah, A. J., and Barr, E. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6(5):271-278.
119. Warzecha, H., Mason, H. S., Lane, C., Tryggvesson, A., Rybicki, E., Williamson, A. L., Clements, J. D., and Rose, R. C. (2003). Oral immunogenicity of human papillomaviruslike particles expressed in potato. J. Virol. 77(16):8702-8711.
120. White, W. I., Wilson, S. D., Bonnez, W., Rose, R. C., Koenig, S., and Suzich, J. A. (1998). In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J. Virol. 72(2):959-964.
121. Wiley, D. J., Douglas, J., Beutner, K., Cox, T., Fife, K., Moscicki, A. B., and Fukumoto, L. (2002). External genital warts: diagnosis, treatment, and prevention. Clin. Infect. Dis. 35(Suppl 2):S210-S224.
122. Winer, R. L., Lee, S. K., Hughes, J. P., Adam, D. E., Kiviat, N. B., and Koutsky, L. A. (2003). Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 157(3):218-226.
123. Winer, R. L., Kiviat, N. B., Hughes, J. P., Adam, D. E., Lee, S. K., Kuypers, J. M., and Koutsky, L. A. (2005). Development and duration of human papillomavirus lesions, after initial infection. J. Infect. Dis. 191(5):731-738.
124. Woodworth, C. D. (2005). HPV innate immunity. Front Biosci. 7:2058-2071.
125. Yang, R., Murillo, F. M., Delannoy, M. J., Blosser, R. L., Yutzy, W. H. T., Uematsu, S., Takeda, K., Akira, S., Viscidi, R. P., and Roden, R. B. (2005). B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J. Immunol. 174(12):7912-7919.
126. Yuan, H., Estes,. A., Chen, Y., Newsome, J., Olcese, V. A., Garcea, R. L., and Schlegel, R. (2001). Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J. Virol. 75(17):7848-7853.
127. Zhang, L. F., Zhou, J., Chen, S., Cai, L. L., Bao, Q. Y., Zheng, F. Y., Lu, J. Q., Padmanabha, J., Hengst, K., Malcolm, K., and Frazer, I. H. (2000). HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18(11-12):1051-1058.
128. Zhou, J., Stenzel, D. J., Sun, X. Y., and Frazer, I. H. (1993). Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J. Gen. Virol. 74:763-768.
129. Zhou, J., Liu, W. J., Peng, S. W., Sun, X. Y., and Frazer, I. (1999). Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J. Virol. 73:4972-4982.
130. Zinkernagel, R. M. (2003). On natural and artificial vaccinations. Annu. Rev. Immunol. 21:515-546.
131. Zur Hausen, H. (2002). Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2(5):342-350.